Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[14C]-Tavapadon AME Study in Healthy Men
NCT04241393Phase 1Completed
- Sponsor
- Cerevel Therapeutics
- Start
- Feb 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tavapadon in Parkinson's disease (PD), sponsored by Cerevel Therapeutics. Primary endpoints: Area under the radioactivity time curve from zero to infinity, Area under the radioactivity time curve from time 0 to last quantifiable concentration and 8 more. Started Feb 2020; status: completed.
02
Drugs
tavapadon
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04241393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04241393.